PCSK9 Use in Diabetes Management - CMEducation Resources IQ&A Interactive Intelligence Zone

Skip to main content

Latest Videos |view all videos

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab?

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab?

What is the unmet need for residual CV risk reduction in post-ACS patients with T2D? In your role as a member of the LDL Guideline Group for AACE, what were the implications of treating diabetic patients with so-called “extreme risk”?”

What is the unmet need for residual CV risk reduction in post-ACS patients with T2D? In your role as a member of the LDL Guideline Group for AACE, what were the implications of treating diabetic patients with so-called “extreme risk”?”

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?

You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

How large is the subgroup of diabetic patients who you feel are likely to appropriate candidates for PCSK9 inhibition to optimize CV risk reduction? And how does the lack of a safety signal influence your recommendations for this group?

How large is the subgroup of diabetic patients who you feel are likely to appropriate candidates for PCSK9 inhibition to optimize CV risk reduction? And how does the lack of a safety signal influence your recommendations for this group?

As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?

What is the rationale for a new category called “extreme risk,” introduced by AACE in which they designate a threshold LDL-C target of 55 mg/dL?

What is the rationale for a new category called “extreme risk,” introduced by AACE in which they designate a threshold LDL-C target of 55 mg/dL?